Lactotripeptides show no effect on human blood pressure: results from a double-blind randomized controlled trial

Randomized Controlled Trial

. 2008 Feb;51(2):399-405.

doi: 10.1161/HYPERTENSIONAHA.107.098988. Epub 2007 Dec 17.

Affiliations

PMID: 18086944
DOI: 10.1161/HYPERTENSIONAHA.107.098988

Randomized Controlled Trial

Mariëlle F Engberink et al. Hypertension. 2008 Feb.

Abstract

Milk-derived peptides with ACE-inhibiting properties may have antihypertensive effects in humans. We conducted a randomized double-blind placebo-controlled trial to examine the blood pressure lowering potential of 2 ACE-inhibiting lactotripeptides, ie, Isoleucine-Proline-Proline and Valine-Proline-Proline. We included 135 Dutch subjects with elevated systolic blood pressure who were otherwise healthy and who received no current antihypertensive treatment. After a 2-week run-in period on placebo, subjects randomly received a daily dose of 200 mL dairy drink with 14 mg lactotripeptides obtained by concentrating fermented milk, enzymatic hydrolysis, or chemical synthesis, or placebo for 8 weeks, followed by a 2-week wash-out. The primary outcome was 8-week change in office systolic blood pressure. Secondary outcomes were change in diastolic blood pressure, home blood pressure, 24-hour ambulatory blood pressure, plasma ACE-activity, and plasma angiotensin II. Blood pressure at baseline was on average 142/84 mm Hg. Lactotripeptides did not significantly change systolic blood pressure (P=0.46) or diastolic blood pressure (P=0.31) compared with placebo. The mean difference (95%-CI) in systolic blood pressure response between treatment and placebo was 2.8 mm Hg (-2.6;8.2) for concentrated fermented milk lactotripeptides, -0.5 mm Hg (-6.0;5.0) for enzymatic lactotripeptides, and 1.6 mm Hg (-3.9;6.9) for synthetic lactotripeptides. Treatment neither had a significant effect on secondary outcome measures. In conclusion, the present study does not support the hypothesis of a blood pressure lowering effect of the lactotripeptides Isoleucine-Proline-Proline and Valine-Proline-Proline.

PubMed Disclaimer

Cited by

Metabolic Syndrome and Biotherapeutic Activity of Dairy (Cow and Buffalo) Milk Proteins and Peptides: Fast Food-Induced Obesity Perspective-A Narrative Review.
Abdisa KB, Szerdahelyi E, Molnár MA, Friedrich L, Lakner Z, Koris A, Toth A, Nath A. Abdisa KB, et al. Biomolecules. 2024 Apr 14;14(4):478. doi: 10.3390/biom14040478. Biomolecules. 2024. PMID: 38672494 Free PMC article. Review.
Molecular targets of antihypertensive peptides: understanding the mechanisms of action based on the pathophysiology of hypertension.
Majumder K, Wu J. Majumder K, et al. Int J Mol Sci. 2014 Dec 24;16(1):256-83. doi: 10.3390/ijms16010256. Int J Mol Sci. 2014. PMID: 25547491 Free PMC article. Review.
Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials.
Fekete ÁA, Givens DI, Lovegrove JA. Fekete ÁA, et al. Nutrients. 2015 Jan 20;7(1):659-81. doi: 10.3390/nu7010659. Nutrients. 2015. PMID: 25608938 Free PMC article. Review.
The impact of lactotripeptides on blood pressure response in stage 1 and stage 2 hypertensives.
Germino FW, Neutel J, Nonaka M, Hendler SS. Germino FW, et al. J Clin Hypertens (Greenwich). 2010 Mar;12(3):153-9. doi: 10.1111/j.1751-7176.2009.00250.x. J Clin Hypertens (Greenwich). 2010. PMID: 20433527 Free PMC article. Clinical Trial.
Perspectives on the Potential Benefits of Antihypertensive Peptides towards Metabolic Syndrome.
Jahandideh F, Wu J. Jahandideh F, et al. Int J Mol Sci. 2020 Mar 22;21(6):2192. doi: 10.3390/ijms21062192. Int J Mol Sci. 2020. PMID: 32235782 Free PMC article. Review.

Lactotripeptides show no effect on human blood pressure: results from a double-blind randomized controlled trial - PubMed (original) (raw)